Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

USCOM LIMITED Investor Presentation 2016

Mar 16, 2016

65979_rns_2016-03-16_0a1e02cf-efb3-489e-9319-7eae19b289c2.pdf

Investor Presentation

Open in viewer

Opens in your device viewer

March 2016 – Canary Investors Presentation

Uscom (UCM) – Global Medical Devices and Revenue Growth

==> picture [842 x 118] intentionally omitted <==

Rob Phillips

PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Uscom Executive Chairman/CEO

The Measure of Life

Disclaimer

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

While Uscom (the "Company”) has taken due care in compiling the information, neither the Company nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Company. Certain information may relate to protected intellectual property rights owned by Uscom. By viewing this presentation the viewer accepts the terms of the accompanying Company NDA. The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Company and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk.

Uscom

“A rapidly growing Australian medical device company with world leading products and a strategic global corporate vision…”

Uscom – Devices the experts use

4

==> picture [757 x 426] intentionally omitted <==

Uscom Recognition

Company of the Year, 2014 Johnson & Johnson Innovation Industry Excellence Awards

“A milestone driven, rapidly growing global medical device company, with real products, real revenue, real growth and an aggressive growth strategy”

==> picture [397 x 51] intentionally omitted <==

==> picture [219 x 97] intentionally omitted <==

Uscom – Devices the experts use

Business Background

  • Premium noninvasive cardiovascular and pulmonary monitoring devices

  • Addressing the growing threat of superbugs, heart failure, hypertension and asthma

  • Validated, clinically accepted, cost and life saving devices with critical applications

  • Aggressive global growth strategy

  • IP protected with regulatory approvals

  • Uscom BP+ and SpiroSonic for market FY 2017

  • +50% revenue growth from USCOM alone, with BP+ and SpiroSonic revenue ahead

  • Corporate Board & Management Financials

  • � ASX listed (UCM) � Rob Phillips, Chairman & CEO � Sales +59% 2015 � Headquartered in Sydney � Sheena Jack, Director � Revenue +48% 2015 � (HCF, Moneytime Health) ($2+m) Market cap of $18m

  • � 100m shares on issue � Christian Bernecker, Director � Cash consumption - <$1m � Rob Phillips, Founder and (Stream) � Gross Margins ~ 78% � Nick Schicht, General Manager �

  • CEO, holds 20% of Cash ~ $1m company

  • Uscom Annual report

Strategic growth

==> picture [40 x 31] intentionally omitted <==

Rapidly strengthening balance sheet Acquisitive, strategic and diversified entity Acquired and integrated Pulsecor (2013) and Thor (2015) Debt free acquisitions – scrip, raising and operations Scientific, operational and strategic synergy New product developments funded from operations Two new product suites ready for revenue/market UK entity established Budapest manufacturing profitable Preparing for volume manufacture of BP+ and SpiroSonic

Uscom – Devices the experts use

Products and Market

Multiple high fidelity noninvasive digital medical devices

Fluid, Sepsis

& Heart Failure

  • US 1.3bn market[*]

  • CAGR of 7.6%[*]

  • CE, FDA, TGA, CFDA

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [5 x 4] intentionally omitted <==

==> picture [4 x 4] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

Hypertension & Vascular Health

COPD

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [4 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

==> picture [5 x 5] intentionally omitted <==

& Asthma

  • US 1.7bn market[*]

  • US 400m market[*]

  • CAGR of 11.5%[*]

  • CAGR of 6.5%[*]

  • CE, FDA, TGA

  • CE, TGA, FDA

USCOM 1A

BP+

Cardiac Output Monitoring Blood Pressure Monitoring

SpiroSonic Pulmonary Monitoring

==> picture [132 x 135] intentionally omitted <==

==> picture [175 x 107] intentionally omitted <==

  • Source: MedTech Insight; Transparency Market Research

Products - USCOM 1A

Heart failure, hypertension, sepsis, fluid Non invasive, accurate, compact, platform technology

Accurate cardiac output

Cardiac stroke volume Systemic vascular resistance Left + right heart measurement

==> picture [308 x 250] intentionally omitted <==

Works with all other hospital equipment Intuitive touch screen Real time data Platform technology with multiple uses

Non invasive, real time, beat-to-beat haemodynamics

Products - Uscom BP+

Hypertension, heart failure and vascular disease Central Blood Pressure and Pulse Wave Analysis The new standard for hypertension

  • FDA, CE Mark, TGA approvals

  • Supra-systolic Oscollometry

  • • Reliable and

  • • accurate

  • • Central and

  • • Brachial BP

  • • Replaces sub-systolic methods (cuff)

  • Home or clinic

  • • PPW Analysis

  • • Results in

  • 30 seconds

  • • No training required

  • • Platform technology with multiple uses

Stand alone, non invasive, accurate, compact system with BP+Reporter

Products - Uscom SpiroSonic

Asthma, COPD, Occupational Lung Disease and drug compliance High fidelity digital Ultrasonic spirometry

  • Digital ultrasonic spirometry

  • Multi-path ultrasonic sensing

  • FDA, CE, and TGA approvals

==> picture [175 x 107] intentionally omitted <==

  • Reliable and accurate

  • Auto calibration

  • Research, home and clinic

  • Wireless transmission

  • SpiroReporter analysis software

==> picture [276 x 78] intentionally omitted <==

==> picture [276 x 78] intentionally omitted <==

  • FloFree tube – low resistance

  • Software guided examination and report

  • Simple disinfection

  • Platform sensors with medical and industrial applications

Stand alone, non invasive, accurate, compact system with SpiroReporter

Future - Big Data

Big data needs high quality sensors Uscom specialises in high quality non-invasive sensors

  • Software analytics

  • Telemetric signals

==> picture [106 x 65] intentionally omitted <==

  • Cloud based processing/diagnosis

  • Personalised clinical advice

==> picture [87 x 89] intentionally omitted <==

  • Medication and dosage

  • Serial monitoring

  • Multiple measures

  • Home care market

  • Subscription service model

==> picture [143 x 137] intentionally omitted <==

  • Global partners – China, US, Euro

  • Multiple software providers – few hardware providers

Stand alone, wireless, accurate, compact, digital devices

De-Risked Technology

Featured in 400+ peer reviewed publications and presentations

==> picture [98 x 117] intentionally omitted <==

==> picture [102 x 125] intentionally omitted <==

==> picture [96 x 113] intentionally omitted <==

==> picture [94 x 110] intentionally omitted <==

==> picture [93 x 111] intentionally omitted <==

==> picture [93 x 112] intentionally omitted <==

==> picture [81 x 107] intentionally omitted <==

Sepsis, Heart failure, Hypertension, Fluid management, Emergency, Pediatrics, Cardiac transplantation, Electrophysiology, Emergency transport, Anesthesia, Liver transplantation, ICU, Pre-eclampsia, Pulmonary hypertension, Nurse outreach, Organ procurement, Haemodialysis, Neonates, infants, Children etc……..

Global

Continued Global Growth

  1. Uscom Aus

  2. Uscom UK

  3. Uscom Budapest 4. Uscom USA

2 •[•] • •[• •] • •• 3

[• ] • • • • •[•] •

[•] • •

[•] •

4 •• • •• • • • • • • • • •

[[•]] • 1

Key Markets • 1. AsiaPAC – 65% •[[•]] • 2/3. Europe – 27% 4. Nth America – 8%

==> picture [97 x 120] intentionally omitted <==

US Focus FY 2017 Stephen Wilson – Former VP Corporate Development Welch Allyn appointed

New US Products

==> picture [220 x 69] intentionally omitted <==

For launch early FY 2017

Uscom – Devices the experts use

US CPT Codes

US Reimbursement Codes for Uscom Technologies

Uscom
Products
CPT
Code
Descriptor Value
(USD)
BP+ 93050 Central BP and PWA $17.91
SpiroSonic 94010 Spirometry $36
94060 Pre andpost bronchodilator administration, spirometry $61
94375 Respiratoryflow volume loop $40
USCOM 76999 Unlisted ultrasound services - TDM* and EDM $76
  • In review

Uscom – Devices the experts use

Growth - UCM

A blue sky story with de-risked operations

==> picture [348 x 289] intentionally omitted <==

----- Start of picture text -----

UCM Revenue and Income
$2,500,000
$2,039,426
$2,000,000
$1,500,000 $1,377,716
$1,010,942
$1,000,000
$500,000
$0
2013 2014 2015
----- End of picture text -----

==> picture [342 x 287] intentionally omitted <==

----- Start of picture text -----

UCM Distribution Agreements
40 38
35
30
27
25
20
15
12
10
5
0
2013 2014 2015
----- End of picture text -----

Current revenue only from USCOM 1A BP+ and SpiroSonic revenue in FY 2017

Growth - UCM

UCM Quarterly Sales Revenue

==> picture [477 x 303] intentionally omitted <==

----- Start of picture text -----

800,000
700,000
600,000
500,000
$ 400,000
300,000
200,000
100,000
0
Q3 13 Q4 13 Q1 14 Q2 14 Q3 14 Q4 14 Q1 15 Q2 15 Q3 15 Q4 15 Q1 16 Q2 16
----- End of picture text -----

Current revenue only from USCOM 1A BP+ and SpiroSonic revenue in FY 2017

Multi-Products

Three product ranges entering profit phase

Concept Product Pilot Validation Regulatory Revenue Global
Distribution
Profit
2016
USCOM 1A ±✓
Uscom BP+ ±✓
SpiroSonic

Investment to Profit

IP shifting to profit

Revenue Targets

==> picture [185 x 129] intentionally omitted <==

----- Start of picture text -----

SpiroSonic – FY 2017
BP+ - FY 2017
----- End of picture text -----

Total Revenue

==> picture [669 x 388] intentionally omitted <==

----- Start of picture text -----

20,000,000
18,000,000
16,000,000
BP+ - FY 2017
14,000,000
12,000,000
SpiroSonic
$ 10,000,000
BP+
USCOM
8,000,000
USCOM
6,000,000
4,000,000
2,000,000
0
2015 2016 2017 2018 2019 2020
----- End of picture text -----*

==> picture [400 x 21] intentionally omitted <==

----- Start of picture text -----

$20m revenue by 2020 = 5 year CAGR of 58%
----- End of picture text -----

The Future

Value Cascade

==> picture [624 x 33] intentionally omitted <==

Products Sales Operations Opportunities USCOM 1A New appointments Global operations Share price growth Uscom BP+ Current distribution Increased products Dividend BP+Reporter Thor distribution Increased scale Transaction SpiroSonic Completion of New distribution Cost effective Capital RaiseSmart manufacture Mobile Major partners Revenue growth Tube Re-imbursement Profitability SpiroReporter US market focus

Converting in off balance sheet assets to revenue.

Right Sector - Health

ASX 10 yr CAGR % pa

==> picture [490 x 294] intentionally omitted <==

----- Start of picture text -----

14.0
12.1
12.0
10.0
8.0
6.0
3.5
% 4.0
2.0
0.1 0.0
0.0
S&P 200 Financial NAB Materials BHP RMD Healthcare
-2.0 Index (Mining) Index
Index
-2.4
-4.0
-4.5 -4.3
-6.0
----- End of picture text -----

UCM sales growth 2014 – 67% 2015 – 59%

  • 1[st] Feb 2006 – 1[st] Feb 2016

  • Exclusive of dividends

Health - Growth sector

Uscom – Devices the experts use

Right Time for Growth

Revenue Growth % pa

==> picture [605 x 357] intentionally omitted <==

----- Start of picture text -----

60
50
40
Uscom
30
Resmed
%
CSL
20
Cochlear
10
0
2013 2014 2015
-10
----- End of picture text -----

Right company, right time…..

Industry Comparators

Reported and Predicted EBITDA

==> picture [539 x 448] intentionally omitted <==

----- Start of picture text -----

2 1.5
1
0
UCM ACG ADH
-1
-0.7
FY 15
-1.1 -1.1
-2 FY16
-1.81
-2.2 FY 17

-3
-2.76
-4
-4
-5
-5.15
-
6
Code Cap Value Current Target
UCM 16m 0.17 0.42
ACG 36m 0.18 0.28
ADR 70m 0.50 1.19
AUD (m)
----- End of picture text -----

  • Estimate *

  • Paterson’s, Taylor Collison, BellPotter.

ASX:UCM

Disconnect between performance and price!

UCM share price

Revenue and Income

==> picture [354 x 267] intentionally omitted <==

----- Start of picture text -----

$3,500,000
$3,100,000
$3,000,000
$2,500,000
$2,039,426
$2,000,000
$1,500,000 $1,377,716
$1,010,942
$1,000,000
$500,000
$0
2013 2014 2015 2016
----- End of picture text -----*

Investment opportunity…..

  • Estimate

Research - UCM

==> picture [598 x 162] intentionally omitted <==

5[th] Oct 2015 5[th] Oct 2016 12mth Change 0.14c (14m) 0.42c (42m) +200%

12 month Projections and price and cap value targets

Ben Kakoschke – 5[th] October, 2015

Uscom

Value investment Experienced management Strong underlying business Strong growth phase ✓ ✓ Invested in growth Premium global markets Diversified and lifesaving technologies Aggressive global growth strategy Two new product ranges for market in the next 12mths Right time – Q3 2016 results imminent

Uscom

“Has acquired global assets to ensure reliable revenue growth for investors for the coming decade.”

Uscom – Devices the experts use

March 2016 – Canary Investors Presentation

Uscom (UCM) – Global Medical Devices and Revenue Growth

==> picture [842 x 118] intentionally omitted <==

Thanks

Rob Phillips

PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland Executive Chairman/CEO

Uscom – Devices the experts use

USCOM 1A Competitive Advantage

Method Manufacturer Technology Rel+Rep Non-
invasive
Simple Cost Portable SV beat
to beat
USCOM 1A Uscom Doppler
BioZ Samsung BioImpedance
NiCOM Cheetah BioReactance
Nexfin Bmeye APP
CardioQ Deltex Doppler
LiDCO LiDCO LiCl dilutio +APP
LiDCOrapid LiDCO APP
PiCCO
(mod Tx + PP)
Pulsion APP
FloTrac Edwards APP
PAC (Tx) Many Thermodilution

Testimonials

“This machine is saving lives, there are no two ways about it.”

Professor Brendan Smith, Anesthetist, Intensivist and Emergency Physician, N.S.W. Dept of Health, Australia

“USCOM has changed the way I look at the cardiovascular status of my patients.

It’s part of the initial shock evaluation and monitored regularly thereafter…. USCOM has now been established as the standard of care.”

Dr Akash Deep, Director of Paediatric ICU, King's College Hospital, London

“The USCOM device is a simple method of accurately and noninvasively measuring central circulation, a goal of cardiology for many years. The device has the potential to change the way we approach management of sepsis, heart failure and hypertension.”

Professor Malcolm West, Cardiologist, Mayne Professor of Medicine at The University of Queensland School of Medicine, Brisbane, Australia and Uscom Medical Advisory Board Member.

“I have used USCOM for over 5 years now on our very sick children, and use it to guide management. We are now beginning multi-centre, global research which will define the way USCOM is used in Paediatric Departments across the world.”

Dr Joe Brierley, Consultant Intensivist, Great Ormond Street Hospital for Sick Children, London, UK.

“The USCOM device is really good; I use it in all my aneasthetics. I think there should be one on every ICU bed and on every anaesthetic patient.”

Dr Steve Woodford, Consultant Anaesthetist, circulatory researcher at Australian School of Advanced Medicine, and Uscom Investor,

“To parents and doctors this machine, USCOM, is priceless. This machine is thought to have saved baby Abbie’s life.

BBC Documentary “New machine helps save babies life”, 2010, Nottingham Children’s Hospital

Uscom – Devices the experts use

BP+ Competitive Advantage

==> picture [94 x 95] intentionally omitted <==

Uscom BP+ TensioMed BPLab IEM Centron AtCor
Australia Hungary Russia Germany UK Australia
USD 3,500 USD 6,000 USD 7,000 USD 7,000 USD 6,300 USD 20,000
1 min 2 min 2 min 2 min 1 min 1 min
Stand-alone ABP, needs computer ABP, needs computer ABP, needs computer Stand-alone Needs computer
CE, FDA, TGA CE CE CE, FDA CE CE, FDA
Aortic + brachial
waveform
Central systolic BP Rough waveform Rough waveform Rough waveform Rough waveform
Physical model Statistical regression Transfer function Transfer function Transfer function Transfer function

Uscom – Devices the experts use

Why ?

Independent research from Cambridge University, Weill Cornell, University of California, Wales Heart Institute – BP+ = Four stars

==> picture [651 x 296] intentionally omitted <==

BP+ is on the international space station

McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson AB. Central blood pressure: current evidence and clinical importance. Euro Heart J 2014;doi10.1093/ eurojeartj/eht565

Thor Competitive Advantage

==> picture [108 x 108] intentionally omitted <==

==> picture [80 x 86] intentionally omitted <==

==> picture [95 x 27] intentionally omitted <==

==> picture [88 x 87] intentionally omitted <==

==> picture [75 x 77] intentionally omitted <==

==> picture [75 x 75] intentionally omitted <==

==> picture [99 x 76] intentionally omitted <==

==> picture [98 x 73] intentionally omitted <==

==> picture [68 x 42] intentionally omitted <==

Uscom
SpiroSonic
Welch Allyn Schiller Sibelmed Vitalograph MIR Carefusion NDD
Australia USA Switzerland Spain USA Italy USA Switzerland
SpiroSonic SpiroPerfect Spirovit SP-1 Dataspir Touch Pneumotrac Spirodoc Microloop EasyOne PLus
USD 1,890 USD 2,100 USD 1,850 USD 2,300 USD 2,030 USD 1,580 USD 2,180 USD 1,990
Dual Path
Ultrasound
Diff Pressure Diff Pressure Turbine Diff Pressure Turbine Turbine Single Path
Ultrasound
Accurate
Auto calibration
SpiroReporter
Fully digital
FreeFlo sensor
Hygeinic
SpO2
Bluetooth
Rechargeable
Multiple
iterations
Multiple
iterations
Multiple
iterations
Multiple
iterations
Multiple
iterations
Conssumable
turbines
Multiple
iterations
Accurate
Consumable
tube

Uscom – Devices the experts use